Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Immunology and Cell Biology|February 9, 2017
Targeting A2 adenosine receptors in cancerDavid Allard, Martin Turcotte, John Stagg
Expert Opinion on Therapeutic Targets|May 7, 2014
Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancerBertrand Allard, Martin Turcotte, John Stagg
Journal of Biomedicine & Biotechnology|November 6, 2012
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growthBertrand Allard, Martin Turcotte, John Stagg
Oncoimmunology|July 29, 2016
CD73-adenosine reduces immune responses and survival in ovarian cancer patientsPierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, et al.
International Journal of Cancer|August 29, 2013
Anti-CD73 therapy impairs tumor angiogenesisBertrand Allard, Martin Turcotte, Kathleen Spring, et al.
Cancer Research|November 23, 2016
PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint InhibitorsRoxanne Charlebois, Bertrand Allard, David Allard, et al.
Cancer Research|September 1, 2017
CD73 Promotes Resistance to HER2/ErbB2 Antibody TherapyMartin Turcotte, David Allard, Deepak Mittal, et al.
Cancer Research|September 13, 2015
CD73 is associated with poor prognosis in high-grade serous ovarian cancerMartin Turcotte, Kathleen Spring, Sandra Pommey, et al.
Pageof 1